Stephens & Co. Reiterates Overweight on Actinium Pharma, Maintains $5 Price Target

Actinium Pharmaceuticals, Inc. +10.77% Pre

Actinium Pharmaceuticals, Inc.

ATNM

1.44

1.50

+10.77%

+4.23% Pre
Stephens & Co. analyst Sudan Loganathan reiterates Actinium Pharma (AMEX: ATNM) with a Overweight and maintains $5 price target.